Literature DB >> 31255735

CBX8 promotes tumorigenesis and confers radioresistance in esophageal squamous cell carcinoma cells through targeting APAF1.

Yixuan Zhang1, Hui Chen1, Hongcheng Zhu2, Xinchen Sun3.   

Abstract

As a transcriptional repressor, Chromobox 8 (CBX8) overexpression is found to be associated with tumorigenesis in several cancers. However, its role in radiotherapy resistance remains poorly characterized. Our study is the first to explore the correlation between CBX8 and radioresistance. We report here that CBX8 is upregulated in Esophageal Squamous Cell Carcinoma (ESCC) tissues and cells and serves as an indicator of poor prognosis for ESCC patients. CBX8 knockdown inhibits cell proliferation, colony formation capability, DNA repair and promotes cell apoptosis. Moreover, the transcriptome sequencing analysis demonstrates that CBX8 downregulates the expression of Apoptotic protease activating factor 1 (APAF1), which is the core protein that mediates mitochondrial apoptotic pathways. APAF1 depletion could abrogate apoptosis induced by CBX8 knockdown in irradiated ESCC cells. Our results provide novel insight into CBX8 as a therapeutic target to improve the radiosensitivity of ESCC.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apoptotic pathway; Apoptotic protease activating factor 1; Chromobox 8; Esophageal squamous cell carcinoma; Radiosensitivity

Mesh:

Substances:

Year:  2019        PMID: 31255735     DOI: 10.1016/j.gene.2019.143949

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  9 in total

1.  Comprehensive analysis of the prognosis for chromobox family in gastric cancer.

Authors:  Kang Lin; Jinfeng Zhu; Cegui Hu; Fanqin Bu; Chen Luo; Xiaojian Zhu; Zhengming Zhu
Journal:  J Gastrointest Oncol       Date:  2020-10

2.  Methylation of Promoters of Apoptosis-Related Genes in Blood Lymphocytes of Workers Exposed to Occupational External Irradiation.

Authors:  D S Isubakova; O S Tsymbal; E V Bronikovskaya; N V Litviakov; I V Milto; R М Takhauov
Journal:  Bull Exp Biol Med       Date:  2021-07-23       Impact factor: 0.804

3.  Repression of PCGF1 Decreases the Proliferation of Glioblastoma Cells in Association with Inactivation of c-Myc Signaling Pathway.

Authors:  Rui Yan; Fengmei Cui; Lijin Dong; Yong Liu; Xuewei Chen; Rong Fan
Journal:  Onco Targets Ther       Date:  2020-01-09       Impact factor: 4.147

4.  KPNA2 interaction with CBX8 contributes to the development and progression of bladder cancer by mediating the PRDM1/c-FOS pathway.

Authors:  Fanchang Zeng; Liumei Luo; Daoyuan Li; Juncheng Guo; Min Guo
Journal:  J Transl Med       Date:  2021-03-17       Impact factor: 5.531

5.  Development and Verification of a Prostate Cancer Prognostic Signature Based on an Immunogenomic Landscape Analysis.

Authors:  Hong Cheng; Yi Wang; Chunhui Liu; Tiange Wu; Shuqiu Chen; Ming Chen
Journal:  Front Oncol       Date:  2021-09-09       Impact factor: 6.244

6.  hsa‑miR‑429 targets CBX8 to promote cell apoptosis in diffuse large B‑cell lymphoma.

Authors:  Yan Liang; Zhuo-Jun Yu; Min Liu; Hui-Min Liu; Jiang-Zhao Zhang; Tao Xiong; Yuan-Yan Tang; Zhi-Ping Huang
Journal:  Mol Med Rep       Date:  2021-10-15       Impact factor: 2.952

7.  Expression profile and prognostic values of Chromobox family members in human glioblastoma.

Authors:  Juanni Li; Zhijie Xu; Lei Zhou; Kuan Hu
Journal:  Aging (Albany NY)       Date:  2022-02-24       Impact factor: 5.682

8.  Identification and Validation of Chromobox Family Members as Potential Prognostic Biomarkers and Therapeutic Targets for Human Esophageal Cancer.

Authors:  Xuefen Fang; Junjun Wang; Jiabing Chen; Mingkai Zhuang; Tingxuan Huang; Zhixin Chen; Yuehong Huang; Biyun Zheng; Xiaozhong Wang
Journal:  Front Genet       Date:  2022-04-06       Impact factor: 4.772

9.  Systematic investigation of the clinical significance and prognostic value of the CBXs in esophageal cancer.

Authors:  Jun Hou; Yinfeng Yang; Honglei Gao; Ting Ouyang; Qiwei Liu; Ran Ding; Hongxing Kan
Journal:  Medicine (Baltimore)       Date:  2022-10-07       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.